Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Large Increase in Short Interest

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totalling 273,000 shares, an increase of 134.9% from the December 31st total of 116,200 shares. Currently, 6.3% of the company’s stock are short sold. Based on an average daily volume of 242,400 shares, the days-to-cover ratio is presently 1.1 days.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Ascendiant Capital Markets reiterated a “buy” rating and set a $6.60 target price on shares of Vivos Therapeutics in a research note on Wednesday, November 20th. Alliance Global Partners reduced their price objective on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 19th.

Vivos Therapeutics Price Performance

Shares of NASDAQ VVOS traded down $0.30 during midday trading on Thursday, reaching $3.94. 262,361 shares of the stock traded hands, compared to its average volume of 321,606. The company’s 50 day moving average is $4.46 and its 200 day moving average is $3.29. Vivos Therapeutics has a one year low of $1.91 and a one year high of $7.74. The stock has a market capitalization of $19.07 million, a PE ratio of -0.69 and a beta of 7.51.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.